{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:48:37Z","timestamp":1790916517204,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is an autoimmune, inflammatory condition characterized by non-scarring hair loss on the scalp, face, or body. It can significantly affect a person\u2019s quality of life (QoL) and mental health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a modified Delphi method, a panel of expert dermatologists developed a practical treatment algorithm to help clinicians deliver personalized, safe care to diverse patients with AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The approach to the algorithm introduces a broader definition of disease severity, incorporating not only Severity of Alopecia Tool (SALT) scores but also quality-of-life impact and the rate of disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Recent therapeutic advances have expanded access to effective, safe treatments for a broader population of AA patients. Ritlecitinib, a Janus kinase 3\/TEC inhibitor, is currently the only oral Janus kinase inhibitor approved for adolescents and adults aged 12\u202fyears and older, whereas baricitinib, a Janus kinase1\/2 inhibitor, is approved for adults aged 18\u202fyears and older. However, questions on the long-term safety of these therapies, access, and personalization still need to be addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Future efforts should validate and refine the algorithm across real-world cohorts and ensure equitable access to personalized treatment for patients with AA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1846243","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:10:04Z","timestamp":1784135404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics"],"prefix":"10.3389","volume":"13","author":[{"given":"Charles W.","family":"Lynde","sequence":"first","affiliation":[{"name":"Lynde Institute for Dermatology and Lynderm Research Inc.","place":["Markham, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Guenther","sequence":"additional","affiliation":[{"name":"Western University","place":["London, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Andriessen","sequence":"additional","affiliation":[{"name":"RBC Consultants, Anneke Andriessen and Co. BV","place":["Malden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Netchiporouk","sequence":"additional","affiliation":[{"name":"McGill University Health Centre","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Prajapati","sequence":"additional","affiliation":[{"name":"University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Skin Health and Wellness Centre, Dermatology Research Institute, and Probity Medical Research","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marni","family":"Wiseman","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, MB, Canada"]},{"name":"SKiNWISE Dermatology","place":["Winnipeg, MB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ringuet","sequence":"additional","affiliation":[{"name":"McGill University Health Centre","place":["Montreal, QC, Canada"]},{"name":"Centre de Recherche Dermatologique du Qu\u00e9bec","place":["Qu\u00e9bec City, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity","volume":"37","author":"Muntyanu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","article-title":"British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012","volume":"166","author":"Messenger","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1525-1470.1994.tb00562.x","article-title":"Prevalence of nail abnormalities in children with alopecia areata","volume":"11","author":"Tosti","year":"1994","journal-title":"Pediatr Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bjd.17463","article-title":"Living with alopecia areata: an online qualitative survey study","volume":"180","author":"Davey","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3685","article-title":"Inhibiting Janus kinases to treat alopecia areata","volume":"20","author":"Divito","year":"2014","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"FrontImmunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.jaad.2010.10.029","article-title":"American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency","volume":"64","author":"Begolka","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines\u2013part II","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic\u2013industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1529-8019.2011.01419.x","article-title":"Topical and intralesional therapies for alopecia areata","volume":"24","author":"Alkhalifah","year":"2011","journal-title":"Dermatol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/1346-8138.13533","article-title":"Intramuscular triamcinolone acetonide: an undervalued option for refractory alopecia areata","volume":"44","author":"Seo","year":"2017","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.15545","article-title":"Minoxidil for patchy alopecia areata: systematic review and meta-analysis","volume":"33","author":"Freire","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2340\/0001555566179180","article-title":"A trial of 1% minoxidil used topically for severe alopecia areata","volume":"66","author":"Vestey","year":"1986","journal-title":"Acta Derm Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0190-9622(93)70238-O","article-title":"Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation","volume":"29","author":"Shapiro","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2020.06.1009","article-title":"Oral minoxidil treatment for hair loss: a review of efficacy and safety","volume":"84","author":"Randolph","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/ijd.14933","article-title":"Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review","volume":"59","author":"Sharma","year":"2020","journal-title":"Int J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/1346-8138.13388","article-title":"Multiple courses of pulse corticosteroid therapy for alopecia areata","volume":"43","author":"Yoshimasu","year":"2016","journal-title":"J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.5114\/ada.2018.77608","article-title":"Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens","volume":"35","author":"Nowicka","year":"2018","journal-title":"Adv Dermatol Allergol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13555-020-00370-2","article-title":"Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata: a systematic review","volume":"10","author":"Nowaczyk","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: a systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2025.11.070","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomised, double-blind, controlled trial","volume":"11","author":"Tsianakas","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/jamadermatol.2022.6687","article-title":"Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial","volume":"159","author":"Joly","year":"2023","journal-title":"JAMA Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/nejmoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"ref32","year":"2023"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","article-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","volume":"4","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jisp.2020.04.005","article-title":"JAK inhibitors for the treatment of pediatric alopecia areata","volume":"20","author":"Hamilton","year":"2020","journal-title":"J Inves Dermatol Symp Proceed"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/all.14814","article-title":"An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata","volume":"76","author":"Glickman","year":"2021","journal-title":"Allergy"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjd.18976","article-title":"The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients","volume":"183","author":"Harada","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref41","year":"2024"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"ref43","year":"2024"},{"key":"ref44","year":"2023"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","volume":"88","author":"Okhovat","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","article-title":"The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care","volume":"187","author":"Macbeth","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00403-021-02247-6","article-title":"The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study","volume":"314","author":"Tzur Bitan","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jaad.2018.12.051","article-title":"Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study","volume":"80","author":"Putterman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jdv.13520","article-title":"Quality of life in patients with alopecia areata: a hospital-based cross-sectional study","volume":"30","author":"Jankovi\u0107","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000497166","article-title":"Psychological profile and quality of life of patients with alopecia areata","volume":"5","author":"V\u00e9lez-Mu\u00f1iz","year":"2019","journal-title":"Skin Appendage Disord"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:10:05Z","timestamp":1784135405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":50,"alternative-id":["10.3389\/fmed.2026.1846243"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1846243","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1846243"}}